CG
NRXP icon

Cutler Group’s NRX Pharmaceuticals NRXP Stock Holding History

Cutler Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-630
Closed -$28K – 5797
2021
Q4 		$28K Sell
630
-1,000
-61% -$72.2K ﹤0.01% 2866
2021
Q3 		$95K Buy
+1,630
New +$212K ﹤0.01% 1957

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

Cutler Group's NRXP Position: Q1 2024 in Review

Cutler Group held its NRX Pharmaceuticals (NRXP) position steady in Q1 2024 at 322 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2069.

Cutler Group first reported a position in NRXP in Q3 2021 and has held it in 11 quarters since. The position peaked at $69K in Q3 2021. 31 funds tracked by Wall St. Rank hold NRXP as of Q1 2024.

  • Cutler Group held 322 shares of NRX Pharmaceuticals worth $1K as of Q1 2024.
  • Cutler Group left its NRX Pharmaceuticals share count unchanged in Q1 2024.
  • NRX Pharmaceuticals made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #2069 holding.
  • Cutler Group first reported a position in NRX Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
  • Cutler Group's NRX Pharmaceuticals position peaked at $69K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.